GGHC
ABVX

Gilder Gagnon Howe & Co’s Abivax ABVX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,030
Closed -$1.49M – 253
2025
Q4 		$1.49M Buy
11,030
+1,206
+12% +$132K 0.02% 207
2025
Q3 		$834K Buy
+9,824
New +$602K 0.01% 224

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

Gilder Gagnon Howe & Co's ABVX Position: Q1 2026 in Review

Gilder Gagnon Howe & Co sold out of Abivax (ABVX) in Q1 2026, closing a stake of 11,030 shares — an estimated $1.49M sold.

Gilder Gagnon Howe & Co first reported a position in ABVX in Q3 2025 and held it in 2 quarters. The position peaked at $1.49M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Gilder Gagnon Howe & Co reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 11,030 Abivax shares in Q1 2026, an estimated $1.49M.
  • Gilder Gagnon Howe & Co first reported a position in Abivax in Q3 2025 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Abivax position peaked at $1.49M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.